International Conference on Metabolic Syndromes October 17-18, 2016 Rome, Italy

Dr. Vincenzo Costigliola has more than 40 years of medical practice after graduating in Medicine at the University of Naples (Italy), and a post-degree specialization in Anesthesiology and Intensive Care from the Università di Pisa (Italy). He is a Founder & President of European Medical Association (Belgium). He has also co-founded the European Association for Preventive, Predictive and Personalized Medicine, and is current President (Belgium). He was formerly the Chief of Medical Services in the Italian Navy. Over the years, Dr Costigliola has widened his specializations into Rheumatology, Dermatology, Proctology, Oncology, Surgery, Drug Abuse, Emergency Treatment, and Disaster Action.He is the Medical Advisor to OTAN and W.E.U. Bruxelles. He is a member of the International Advisory Board of the King Abdulaziz University, Jeddah (Saudi Arabia); a Board member of the European Biotechnology Thematic Network Association (Italy); and a member of the Editorial Advisory Board of the Journal of Psychiatry in Primary Care. He is a renowned speaker at numerous International Conferences and Congresses. He is multilingual and is proficient in 5 languages; English, Italian, French, Spanish and Portugese.

Medicine, Clinical Trials, Internal Medicine,Emergency Medicine,Family Medicine,Holistic Medicine,Diabetes

Dr. Arturo Solís Herrera, MD, PhD., has been Graduated from Institute Polytechnic Nacional, from CDMX, in 1978 as Medicine Doctor, with the specialties including Ophthalmology, in the National University of Mexico, and Neuro-Ophthalmology, at INNN, México. Later on he obtained his Master Science Degree from University of Aguascalientes, México, and thereafter a PhD in Pharmacology, Universidad de Guadalajara, México. Dr. Solís Herrera is director and founder of Human Photosynthesis® Research Center, in Ags., México, in 2007; where he has continued his research until today.

Human Photosynthesis, Metabolism

Dominico Merante joined DSD in March 2007 as Senior Director of Clinical Development at the newly opened R&D office in Gerrards Cross, United Kingdom. In July 2010 became European Head of Frontier/Opportunity and Metabolism. In 2011-2012 successfully led, as global clinical lead, the US phase 2 adaptive study of mirogabalin in painful diabetic neuropathy. Study results were published in Diabetes Care in December 2014. 3 years + 3 months of clinical management/leadership training experience in the Italian Navy working at the Infirmary of the Naval Academy as Lieutenant Medical Officer and on Nave Ammiraglio Magnaghi as Chief Medical Officer.

diabetes, endocrinology, cardiovascular, dyslipidemias, hypertension, neuroscie

Arie Franx holds an MD-degree of the Free University in Amsterdam and a PhD-degree of the University of Utrecht. He specialized in obstetrics/ gynaecology and attended leadership programs at INSEAD (Fontainebleau, France) and at Harvard Business School and Harvard School of Public Health (Boston, MA, USA). He is currently Professor of Obstetrics, Chair of the Division Woman and Baby en Director of the Ob/Gyn Specialty Training in the University Medical Centre Utrecht. His research interest include pregnancy complications, cardiovascular health in women, and organization and quality of care. He has published over 150 papers in international peer-reviewed scientific journals .

pregnancy complications, cardiovascular health in women, and organization and quality of care

Dr El Habachi is a Professor in the Department of Physiology and the Academic Director of the Alexandria Clinical Research Centre in the Faculty of Medicine, Alexandria University, Egypt. She is a multilingual Professor with a track record of establishing multinational partnerships, and teaches in both English and French. She has been pivotal in establishing the University Clinical Research Centre. Part of her pre-doctoral training was conducted in the Heart Science Centre, Imperial College, UK. In May 2006 she studied clinical research and GCP, University of Maryland USA. She has a broad research experience in national and international projects.

Nutrition,Stress Management,ClinicalTrials,Clinical Reseach

Dr. Kang Choon Lee is Haengdan Distinguished Professor at the SungKyunKwan University (SKKU), Korea, and was director of the Center of Excellence for Future Pharmaceutical Education and Research in the College of Pharmacy at SKKU. He served as a professor and dean at the College of Pharmacy as well as the director of the Institute of Pharmaceutical Science. Prior to joining SKKU in 1992, Dr. Lee was a principal scientist at Dong-A Pharmaceutical Co. for ten years before joining Chonnam National University as a professor of pharmacy. For over 30 years, Dr. Lee’s Drug Targeting Laboratory has been focused on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs. Dr. Lee is internationally recognized as one of the leading experts in site-specific peptide/protein PEGylation and firstly demonstrated the therapeutic potential of novel site-specific PEGylated drugs such as GLP-1 and TRAIL. He has published over 150 papers in peer-reviewed journals and served as an invited speaker at many international conferences. Dr. Lee is an inventor on more than 20 patents related to specific bioconjugation and modification of peptide/protein drugs. He served as president of the Korean-American Pharmaceutical Scientists Association and vice-president of the Pharmaceutical Society of Korea and Korean Society of Pharmaceutical Science and Technology. Dr. Lee is a recipient of the Distinguished Pharmaceutical Scientist Award from the Pharmaceutical Society of Korea in 2002 and honored as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2003. He currently serves on the editorial advisory board of many international scientific journals including Pharmaceutical Research, Pharmaceutical Development and Technology, PharmSciTech and Journal of Drug Delivery. In 2012, he founded B&L DeliPharm Inc. Korea, a pharmaceutical company focused on clinically translating and commercializing site-specific engineered peptide/protein drugs developed by his laboratory and also he co-founded and serves as a Board Member of Theraly Pharmaceuticals, USA.

Metabolism,Clinical Research, Endocrinology